Litigation

Humana Inc. v. Celgene Corp.

partially dismissed; amended complaints filed

2:19-cv-07532

Patents at issue (1)

Plaintiffs (1)

Defendants (1)

Summary

Antitrust follow-on litigation where purchasers/insurers allege Celgene used the '740 and related method-of-treatment patents, serial sham suits, and reverse-payment settlements to delay generic lenalidomide. The court dismissed the insurer and MSP operative complaints on June 6, 2024, with later amended complaints filed.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).